ImmunoScape has signed a Memorandum of Understanding with a US-based cancer centre to launch an investigator-initiated clinical trial targeting WT1-positive solid tumours using its TCR-based immunotherapy platform.

• Technology: Utilises a “Seed and Boost” approach combining engineered autologous T-cells targeting WT1 with a fusion protein to selectively expand and activate these cells.
• Timeline: The clinical trial is expected to dose its first patients by September 2026.
• Scope: Targets multiple difficult-to-treat cancers, including ovarian, mesothelioma, pancreatic, and colorectal tumours.

This summary is based on a news article by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.